Cargando…
Special issue “The advance of solid tumor research in China”: Participants with a family history of cancer have a higher participation rate in low‐dose computed tomography for lung cancer screening
We aimed to determine participation in low‐dose computed tomography (LDCT) of individuals with a family history of common cancers in a population‐based screening program to provide timely evidence in high‐risk populations in China. The analysis was conducted using data from the Cancer Screening Prog...
Autores principales: | Guo, Lan‐Wei, Meng, Qing‐Cheng, Zheng, Li‐Yang, Chen, Qiong, Liu, Yin, Xu, Hui‐Fang, Kang, Rui‐Hua, Zhang, Lu‐Yao, Liu, Shu‐Zheng, Sun, Xi‐Bin, Zhang, Shao‐Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790604/ https://www.ncbi.nlm.nih.gov/pubmed/35362560 http://dx.doi.org/10.1002/ijc.34010 |
Ejemplares similares
-
Determinants of participation and detection rate of upper gastrointestinal cancer from population‐based screening program in China
por: Guo, Lanwei, et al.
Publicado: (2019) -
A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
por: Unseld, Matthias, et al.
Publicado: (2020) -
A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
por: Eng, Cathy, et al.
Publicado: (2016) -
Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years
por: Basse, Clémence, et al.
Publicado: (2019) -
A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
por: Weekes, Colin, et al.
Publicado: (2019)